Bivalent mRNA-1273.214 vaccine effectiveness against SARS-CoV-2 omicron XBB* infections. Academic Article uri icon

Overview

abstract

  • Effectiveness of the 50-μg mRNA-1273.214 bivalent vaccine against SARS-CoV-2 infection was modest at 25% in a matched, retrospective, cohort study in Qatar comparing infection incidence in the bivalent cohort to that in the national no-recent-vaccination resident cohort. XBB* immune evasion, immune imprinting effects, or both, may explain findings.

authors

  • Chemaitelly, Hiam Souheil
  • Ayoub, Houssein H
  • AlMukdad, Sawsan
  • Faust, Jeremy Samuel
  • Tang, Patrick
  • Coyle, Peter
  • Yassine, Hadi M
  • Al Thani, Asmaa A
  • Al-Khatib, Hebah A
  • Hasan, Mohammad R
  • Al-Kanaani, Zaina
  • Al-Kuwari, Einas
  • Jeremijenko, Andrew
  • Kaleeckal, Anvar H
  • Latif, Ali N
  • Shaik, Riyazuddin M
  • Abdul-Rahim, Hanan F
  • Nasrallah, Gheyath K
  • Al-Kuwari, Mohamed G
  • Butt, Adeel A
  • Al-Romaihi, Hamad E
  • Al-Thani, Mohamed H
  • Al-Khal, Abdullatif
  • Bertollini, Roberto
  • Abu-Raddad, Laith Jamal

publication date

  • August 9, 2023

Research

keywords

  • COVID-19

Identity

Digital Object Identifier (DOI)

  • 10.1093/jtm/taad106

PubMed ID

  • 37555656